Serax Addiction
Understanding oxazepam dependence, withdrawal, side effects, and evidence-based residential treatment at Phuket Island Rehab.
Clinically reviewed by Dr. Ponlawat Pitsuwan, Physician and Addiction Medicine Specialist, Phuket Island Rehab.
Serax is the historical brand name for oxazepam, an intermediate-acting benzodiazepine used to treat anxiety, alcohol withdrawal, and short-term insomnia. Although the brand has been discontinued in most markets, generic oxazepam remains widely prescribed, particularly to older adults and to patients with significant liver disease, because it avoids the active metabolites of diazepam and chlordiazepoxide. Like all benzodiazepines, oxazepam has a recognised potential for dependence, and withdrawal symptoms can be severe enough to be dangerous. Common side effects include drowsiness, ataxia, cognitive impairment, and emotional blunting, and the drug carries significant overdose risk when combined with alcohol, opioids, or other central nervous system depressants. At Phuket Island Rehab, our clinicians treat oxazepam dependence as part of the wider benzodiazepine and alcohol picture, with a slow medical detox under supervision, parallel therapy for the underlying anxiety or trauma that drove the original prescription, and a residential setting that allows the medication and substance review to happen in one place.
What is Serax (oxazepam)?
Serax was the original brand name for oxazepam, an intermediate-acting benzodiazepine first introduced into clinical use in the 1960s. The brand has been discontinued in the United States and in most other markets, but generic oxazepam remains available worldwide and is widely prescribed. The drug is approved for the management of anxiety disorders, the short-term treatment of insomnia, and the management of alcohol withdrawal. Oxazepam is available as 10 mg, 15 mg, and 30 mg oral capsules and tablets, and the usual dose range for anxiety is 10 mg to 30 mg three or four times daily.
Oxazepam has a particular niche in benzodiazepine prescribing because it is metabolised by direct glucuronide conjugation in the liver rather than by the cytochrome P450 oxidative pathways that handle most other benzodiazepines. This metabolic difference means oxazepam has no clinically important active metabolites, accumulates less in patients with liver disease, and interacts with fewer other medications than diazepam or chlordiazepoxide. For these reasons, oxazepam is often chosen for older adults, for patients with significant liver impairment including alcoholic liver disease, and for patients on multiple medications where drug interactions are a concern.
How oxazepam works in the brain
Oxazepam binds to the benzodiazepine recognition site on the GABA-A receptor, the principal inhibitory receptor of the human central nervous system. The drug enhances the action of gamma-aminobutyric acid at this receptor, increasing the frequency with which the chloride channel opens, deepening neural inhibition, and producing anxiolysis, sedation, muscle relaxation, and anticonvulsant activity. The clinical effects are similar to those of other benzodiazepines, with the differences between agents lying mostly in onset of action, half-life, and metabolic profile rather than in the underlying mechanism.
Oxazepam has a slow onset of action compared with diazepam or lorazepam, reaching peak plasma levels within two to three hours after oral administration. The elimination half-life is six to twenty hours in healthy adults, classifying the drug as intermediate-acting. Because the metabolism is by glucuronide conjugation alone, there are no significant active metabolites and no significant accumulation in older adults or in patients with hepatic impairment. This metabolic profile is the principal clinical reason oxazepam is selected over other benzodiazepines in particular patient populations.
| Parameter | Value | Clinical implication |
|---|---|---|
| Onset of action | Slow (2 to 3 hours) | Less suitable for acute distress; useful for steady-state anxiolysis |
| Half-life | 6 to 20 hours | Intermediate; requires twice or three times daily dosing |
| Metabolism | Glucuronide conjugation | No oxidative metabolism; safe in liver disease and older adults |
| Active metabolites | None significant | No accumulation; predictable dose-response |
| Doses | 10 to 30 mg, three or four times daily | Range guided by indication and tolerance |
Recognised uses of oxazepam
Oxazepam is approved for several recognisable clinical indications. The first is the management of anxiety disorders, particularly generalised anxiety with significant somatic symptoms, where the slow onset is acceptable and where the lack of active metabolites is helpful. The second is the short-term treatment of insomnia, though longer-acting agents are generally preferred for sleep because the slow onset of oxazepam means the drug may not act before the patient wants to sleep. The third is the management of alcohol withdrawal, where oxazepam is often the preferred benzodiazepine in patients with significant liver disease because the lack of oxidative metabolism removes the risk of accumulation that complicates diazepam dosing in this population.
The drug is not approved for long-term anxiety management, and current clinical guidance from regulators and from professional bodies including the Royal College of Psychiatrists and the American Psychiatric Association recommends benzodiazepine treatment for anxiety be limited to short courses of two to four weeks. Despite this guidance, oxazepam is one of the benzodiazepines most commonly continued long-term in older adults, partly because the favourable metabolic profile leads prescribers to underestimate the risk of dependence. The dependence develops with daily use over weeks to months and is no less real in oxazepam than in any other benzodiazepine.
Is Serax (oxazepam) addictive?
Yes. Oxazepam is a benzodiazepine, and like all benzodiazepines it can produce both physical dependence and a behavioural pattern of addiction with repeated use. Daily dosing for two to four weeks is enough to establish physical dependence in most patients, and the dependence is functionally indistinguishable from dependence on other benzodiazepines. The relatively slow onset of action and the absence of strong euphoria mean that oxazepam is less attractive than diazepam, alprazolam, or lorazepam for recreational misuse, but the drug is still misused in some populations and dependence develops reliably with continued daily use whatever the original indication.
Addiction, in the behavioural sense defined by the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders, is a separate question from physical dependence. A patient who takes oxazepam exactly as prescribed for a clear indication, who never escalates dose, who never combines it inappropriately, and who never seeks the drug outside the prescription is physically dependent but does not meet criteria for substance use disorder. A patient who takes more than the prescribed dose, who combines oxazepam with alcohol or other depressants for amplified effect, who hides use from prescribers, or who continues despite clear harms is on the disordered-use trajectory.
Three patterns of oxazepam misuse are common in addiction medicine. The first is iatrogenic dependence in older adults, where the medication was prescribed for transient anxiety years ago and has continued indefinitely without review, often resulting in cognitive impairment that is misread as early dementia. The second is co-use with alcohol, where patients with alcohol use disorder use the benzodiazepine to manage the morning anxiety and withdrawal symptoms of their drinking pattern, creating a layered dependence that is more difficult to treat than either substance alone. The third is recreational polydrug use, particularly in younger adults combining oxazepam with opioids or stimulants, where the slow onset is less reinforcing but the drug is still part of the chemical mix.
Common Serax side effects
Common side effects of oxazepam include drowsiness, dizziness, light-headedness, ataxia, slurred speech, blurred vision, fatigue, and headache. Cognitive side effects including impaired memory, slowed information processing, and reduced executive function are particularly important in older adults, where they can be severe enough to cause confusion and falls. Emotional blunting, where patients report feeling less anxious but also less alive, is common with sustained use and is one of the reasons patients eventually seek to come off the medication. Less common but more serious effects include paradoxical reactions with agitation or aggression, particularly in older adults and in patients with brain injury, and rare allergic reactions.
The drug-interaction profile is more favourable than for diazepam or chlordiazepoxide because oxazepam does not depend on cytochrome P450 oxidation. The main interactions of clinical importance are pharmacodynamic: additive sedation and respiratory depression with alcohol, opioids, other benzodiazepines, sedating antihistamines, and certain antidepressants. Older adults are particularly sensitive to these additive effects, and benzodiazepines including oxazepam appear on the Beers Criteria of potentially inappropriate medications in older adults precisely because of the additive cognitive and balance effects.
Serax withdrawal and tapering
Oxazepam withdrawal is a benzodiazepine withdrawal syndrome, and like all benzodiazepine withdrawal it follows a recognisable course. Symptoms typically begin one to three days after the last dose, which is later than for short-acting agents such as alprazolam and earlier than for long-acting agents such as diazepam. The early phase brings anxiety, restlessness, insomnia, sweating, tremor, gastrointestinal upset, and raised heart rate. The peak phase between days three and seven adds perceptual disturbances, sensitivity to light and sound, depersonalisation, severe rebound anxiety, and at the extreme end seizures, hallucinations, and delirium. The resolution phase between weeks two and four sees gradual improvement, though protracted withdrawal symptoms can persist for months in some patients.
The tapering plan for oxazepam follows the general benzodiazepine principle of slow, symptom-driven dose reduction. A typical approach is to reduce the daily dose by five to ten percent every one to two weeks, with the rate slowed at the lower end of the dose range where the proportional reduction has the greatest pharmacological impact. Patients on oxazepam for years often need a taper schedule of six to twelve months, sometimes longer, and patients who have failed previous attempts at faster tapers usually do better the second time when the schedule is more conservative. For patients with severe symptoms or with concurrent dependence on other substances, conversion to a longer-acting benzodiazepine such as diazepam before tapering can produce a smoother course, though this option needs to be weighed against the metabolic disadvantage of diazepam in patients with liver disease.
| Phase | Timing after last dose | Typical features |
|---|---|---|
| Early | 1 to 3 days | Anxiety, insomnia, tremor, sweating, raised heart rate, GI upset |
| Peak | Days 3 to 7 | Worsening symptoms, perceptual changes, risk of seizures, severe rebound anxiety |
| Resolution | Weeks 2 to 4 | Symptoms ease; protracted symptoms can persist for months |
Treatment for Serax addiction at Phuket Island Rehab
Treatment for oxazepam dependence at our clinic follows the same general framework as benzodiazepine treatment in general. The first task at admission is a careful medication and substance history that establishes the full picture, including all benzodiazepines and other depressants on board, any alcohol use, and any other substances of concern. Many patients with oxazepam dependence are also drinking heavily or are dependent on other benzodiazepines, and the detox plan addresses the medications together rather than in sequence. Patients with co-occurring depression, anxiety, trauma, or other mental health conditions are managed by a coordinated team that addresses the underlying condition properly rather than relying on the benzodiazepine to mask it.
The medical detox itself is a slow tapered withdrawal under supervision. Patients are stabilised on their current equivalent dose, the polydrug picture is addressed, and the dose is reduced gradually over weeks to months at a pace tailored to the individual. Conversion to a longer-acting benzodiazepine such as diazepam is considered for patients with severe inter-dose rebound or with significant polydrug dependence, balanced against the metabolic concerns in patients with liver disease. Adjunct medications including antidepressants, anticonvulsants such as pregabalin or gabapentin, and selected non-addictive sedatives are used where appropriate to manage breakthrough symptoms during taper, though none of these is a substitute for the slow benzodiazepine reduction itself.
Therapy runs in parallel with the medical detox from day one. Patients work with our counsellors on the underlying anxiety, trauma, or sleep disorder that drove the original prescription, on the cross-tolerance and cross-vulnerability to alcohol and other depressants that persists after taper, on the cognitive recovery that follows benzodiazepine reduction in long-term users, and on the relapse-prevention plan that has to carry them through the first year of recovery. Dual diagnosis treatment integrating addiction and mental health care is the default. Treatment options include medical detox, residential rehabilitation, partial hospitalisation, and intensive outpatient programs, with the level of care matched to the severity of dependence and to the complexity of the medication and substance picture.
Why international clients come to Thailand for benzodiazepine treatment
Patients from the United States, the United Kingdom, Australia, and continental Europe travel to Phuket Island Rehab for oxazepam and broader benzodiazepine treatment for several reasons. The first is the difficulty of accessing a slow, properly supervised benzodiazepine taper inside the routine health system in many home countries, where short outpatient appointments are the norm and where domestic prescribers may be reluctant to commit to the months-long taper most long-term benzodiazepine users need. The second is privacy: older adults with iatrogenic dependence, professionals with long-standing prescriptions, and patients who layered alcohol or other depressants on top of the benzodiazepine often cannot complete a domestic rehab without their family doctor or workplace becoming aware.
The third is the residential continuum of care our programme provides. Patients arrive, receive a comprehensive medical and medication review, transition into residential rehab with parallel therapy, step down through partial hospitalisation or intensive outpatient services as appropriate, and leave with a written aftercare plan. The Phuket setting, climate, and distance from the prescribing environment make it materially easier to interrupt a long-standing benzodiazepine pattern than an outpatient programme at home. The cost of a full residential programme in Phuket, including medical detox, therapy, accommodation, food, and excursions, is a fraction of the equivalent domestic programme, which often allows a longer stay and a fuller recovery arc.
When benzodiazepine use has become more than helpful
Many of the people who reach out to our team are not in obvious crisis. They are still working, still functioning, still seeing the same prescribers. What has changed is that the original problem the benzodiazepine was supposed to solve is either no longer present or no longer being solved. Anxiety is sometimes worse than it was before the medication started, sleep is worse, and the days have a flatness that nobody welcomes. Heavy or daily drinking has often layered on top, and the patient is increasingly aware that the medication is doing harm as well as good. If you or someone you love is in this position, the next step is a conversation with a clinician who is honest about how benzodiazepines work and what coming off them really takes.
Heavy drinking alongside benzodiazepine use is the single most important comorbidity in this group. Alcohol potentiates GABA-A signalling at the same receptor complex, the two together suppress respiration more than either alone, and they share withdrawal pathways that compound when the patient stops both at once. Any honest treatment plan asks about drinking patterns from the first interview and treats the alcohol use as part of the same problem. Patients with alcohol use disorder treated with oxazepam during the withdrawal phase sometimes continue the benzodiazepine long-term, and that drift from short-term detox medication to chronic dependence is one of the most common ways oxazepam misuse develops.
Summary
Serax is the historical brand name for oxazepam, an intermediate-acting benzodiazepine with legitimate roles in short-term anxiety management, short-term insomnia treatment, and management of alcohol withdrawal in patients with significant liver disease. The drug’s favourable metabolic profile, with glucuronide conjugation rather than cytochrome P450 oxidation, has led to its widespread use in older adults and in patients with hepatic impairment, but the same favourable profile has also encouraged long-term continuation that is rarely indicated. Like all benzodiazepines, oxazepam can produce dependence, withdrawal that can be severe and prolonged, cognitive impairment, and overdose risk when combined with alcohol or opioids. Treatment is a slow tapered withdrawal under supervision, parallel therapy for the underlying anxiety or insomnia, and the residential structure that allows the medication and substance picture to be reviewed properly. A taper of months or longer, rather than weeks, is the realistic timeframe for patients who have been on the drug for years.
As our physician Dr. Ponlawat Pitsuwan puts it, “Oxazepam is one of those medications that has slipped into long-term prescribing patterns that nobody really chose. The patients I see have often been on the drug for a decade or more without anyone questioning whether it should still be there. The work of recovery is partly about coming off the medication, and partly about answering the underlying question of what the medication has been doing for the patient all this time.”
Frequently asked questions about Serax (oxazepam)
Is Serax still available?
The original Serax brand has been discontinued in the United States and most other markets, but generic oxazepam remains widely available worldwide. Patients who were previously prescribed Serax have generally been switched to generic oxazepam, which is pharmacologically identical. The drug is still prescribed for anxiety disorders, short-term insomnia, and the management of alcohol withdrawal, particularly in older adults and patients with significant liver disease.
Is Serax addictive?
Yes. Oxazepam is a benzodiazepine, and like all benzodiazepines it can produce physical dependence with daily use over weeks to months. The slow onset of action makes the drug less attractive than other benzodiazepines for recreational misuse, but dependence develops reliably with continued daily use whatever the original indication. Patients who take oxazepam exactly as prescribed can still become physically dependent on the medication, and the dependence is real even when the use is medically appropriate.
What are common side effects of oxazepam?
Common side effects include drowsiness, dizziness, ataxia, slurred speech, blurred vision, fatigue, and cognitive impairment. Older adults are particularly sensitive to the cognitive and balance effects, and benzodiazepines are commonly implicated in falls in this population. Emotional blunting is common with sustained use. Less common but more serious effects include paradoxical reactions with agitation, severe rebound anxiety on dose reduction, and respiratory depression when combined with alcohol, opioids, or other depressants.
How long does oxazepam stay in your system?
Oxazepam has an elimination half-life of six to twenty hours in healthy adults, and a single dose is typically cleared from the bloodstream within two to four days. Routine urine drug screens detect benzodiazepines, including oxazepam, for one to three days after a single dose, and longer in patients on regular dosing. Older adults, patients with liver disease, and patients taking interacting medications may have prolonged drug clearance, though oxazepam is more predictable in this respect than diazepam or chlordiazepoxide because of its metabolic profile.
What does oxazepam withdrawal feel like?
Oxazepam withdrawal feels like the original anxiety, intensified, with added physical symptoms including tremor, sweating, raised heart rate, sleep disruption, and perceptual changes. Symptoms typically begin one to three days after the last dose and peak between days three and seven. At the severe end, withdrawal can produce seizures, severe rebound anxiety, depersonalisation, and a sense of overwhelming distress that patients describe as unbearable. Symptoms can be severe enough to be dangerous, and unsupervised withdrawal is not recommended. Some patients experience protracted withdrawal symptoms lasting months after the last dose.
How is oxazepam dependence treated?
Treatment for oxazepam dependence is a slow tapered withdrawal under medical supervision, with parallel therapy for the underlying anxiety or insomnia that drove the original prescription. A typical taper reduces the dose by five to ten percent every one to two weeks, with the rate slowed at the lower end of the dose range. Patients on the medication for years often need a taper schedule of six to twelve months. Conversion to a longer-acting benzodiazepine such as diazepam before tapering can help in some cases. Residential treatment is generally indicated for patients with severe dependence, polydrug use, or significant co-occurring mental health conditions.
Sources
United States Food and Drug Administration. Serax (oxazepam) prescribing information (archived). https://www.accessdata.fda.gov
National Institute on Drug Abuse (NIDA). Benzodiazepines and Opioids. https://nida.nih.gov/research-topics/opioids/benzodiazepines-opioids
British National Formulary. Oxazepam. https://bnf.nice.org.uk/drugs/oxazepam/
American Geriatrics Society Beers Criteria. Potentially inappropriate medications in older adults. https://geriatricscareonline.org
Royal College of Psychiatrists. Benzodiazepines: dependence and withdrawal. https://www.rcpsych.ac.uk
Substance Abuse and Mental Health Services Administration (SAMHSA). Co-occurring disorders. https://www.samhsa.gov/medications-substance-use-disorders
Ashton CH. Benzodiazepines: how they work and how to withdraw (the Ashton Manual). https://www.benzo.org.uk/manual/
Oxazepam dependence: clinical context and risk groups
Patients prescribed oxazepam for years may experience side effects including cognitive impairment, emotional blunting, balance problems, and rebound anxiety. The risk of dependence is associated with daily use over weeks to months and includes physical and psychological dimensions. Common features of oxazepam misuse include taking more than the prescribed dose, combining the drug with alcohol or other drugs, and continuing the medication for years beyond the original indication. People with a history of substance use disorder, including alcohol use disorder, are at higher risk of moving from prescribed use into dependence. Help with oxazepam dependence is most effective when the treatment includes therapy for the underlying anxiety or depression that prompted the prescription, alongside the medical detox. Healthcare professionals managing the taper need to coordinate with mental health, addiction medicine, and primary care to deliver a sustainable plan. The benzodiazepine class as a whole has well-documented risks of dependence and withdrawal, and oxazepam is no exception despite its favourable metabolic profile. Patients seeking treatment for oxazepam dependence benefit from a residential programme that includes medical detox, parallel therapy, dual diagnosis care, and structured aftercare.
Serax addiction — key entities and related terms
Serax, oxazepam, benzodiazepine, GABA-A receptor, glucuronide conjugation, intermediate-acting benzodiazepine, anxiety disorder, generalised anxiety, insomnia, alcohol withdrawal, alcoholic liver disease, hepatic impairment, older adults, 10 mg, 15 mg, 30 mg, drowsiness, ataxia, cognitive impairment, emotional blunting, falls in older adults, Beers Criteria, dependence, tolerance, withdrawal syndrome, seizure risk, perceptual disturbance, depersonalisation, rebound anxiety, protracted withdrawal, taper, diazepam conversion, Ashton Manual, polydrug use, opioid combination, alcohol combination, alcohol use disorder, AUD, dual diagnosis, medical detox, residential rehab, partial hospitalisation, intensive outpatient program, Phuket Island Rehab, John A. Smith, Dr. Ponlawat Pitsuwan, NIDA, SAMHSA, FDA, NHS, BNF, NICE, RCPsych.